[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545344":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":20,"locations":26,"responsibleParty":58,"collaborators":60,"id":64,"slug":7,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":7,"enrollmentInfo":73,"targetDuration":76,"studyType":77,"phases":7,"briefSummary":78,"conditions":79,"keywords":84,"overallStatus":45,"whyStopped":7,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"AIO-Studien-gGmbH","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"data collection","Demography, Social history, Riskfactors, Relevant medical history, Oncological family history, Disease \\& treatment history, Molecular Pathology and Results, Treatment data, Response data, progession free survial, overall survival.",[13,17],{"name":14,"affiliation":15,"role":16},"Victor Grünwald, Prof. Dr.","Universitätsklinikum Essen","STUDY_DIRECTOR",{"name":18,"affiliation":15,"role":19},"Michael Pogorzelski, Dr.","PRINCIPAL_INVESTIGATOR",[21],{"name":22,"role":23,"phone":24,"phoneExt":7,"email":25},"Project Manager","CONTACT","+49 (0)30 814534431","kht-register@aio-studien-ggmbh.de",[27,43],{"facility":15,"status":28,"city":29,"state":7,"zip":30,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"NOT_YET_RECRUITING","Essen","45147","Germany",{"type":33,"coordinates":34},"Point",[35,36],7.01228,51.45657,{"lat":36,"lon":35},[39],{"name":40,"role":23,"phone":41,"phoneExt":7,"email":42},"Michael Pogorzelski, Dr. med.","+49 (0) 157 38 79 55 41","Michael.Pogorzelski@uk-essen.de",{"facility":44,"status":45,"city":46,"state":7,"zip":47,"country":31,"cosmosGeoPoint":48,"geoPoint":52,"contacts":53},"Onkologie\u002FStudienzentrum am Raschplatz GbR","RECRUITING","Hanover","30161",{"type":33,"coordinates":49},[50,51],9.73322,52.37052,{"lat":51,"lon":50},[54],{"name":55,"role":23,"phone":56,"phoneExt":7,"email":57},"Eyck von der Heyde, Dr. med.","+49 (0) 511 86649985","vdheyde@onkologie-am-raschplatz.de",{"type":59,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[61],{"name":62,"class":63},"Merck Sharp & Dohme LLC","INDUSTRY","100545344",false,"NCT06380686","Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome","Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based","HEAT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Able to understand and willing to sign written informed consent\n* Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx)\n* Patients not amenable for curative treatment who receive palliative systemic treatment or best supportive care\n* Informed consent no later than four weeks after start of first-line palliative systemic treatment. For patients receiving \"best supportive care only\": no later than six weeks after diagnosis\u002Frecurrence or metastatic disease\n\nExclusion Criteria: none","ALL","18 Years",{"count":74,"type":75},120,"ESTIMATED","36 Months","OBSERVATIONAL","Prospective, open, non-interventional, multi-center clinical registry study with the aim to establish a comprehensive research platform reflecting the real-world treatment landscape for recurrent\u002Fmetastatic head and neck tumor patients.",[80,81,82,83],"Squamous Cell Carcinoma of the Oral Cavity","Squamous Cell Carcinoma of the Oropharynx","Squamous Cell Carcinoma of the Hypopharynx","Squamous Cell Carcinoma of the Larynx",[85],"SCCHN","2024-11-11",{"date":88,"type":89},"2024-11-13","ACTUAL",{"date":91,"type":89},"2024-11-07",{"date":93,"type":75},"2030-11",{"name":5,"class":6},2]